Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Illumina, Sequenom resolve patent disputes
January 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

SAN DIEGO—Illumina Inc. and Sequenom Inc. have reached an agreement that will settle all pending infringement claims and other disputes between Sequenom and Verinata Health Inc. The companies will pool the intellectual property directed to noninvasive prenatal testing (NIPT) they own and have in-licensed, including patents that remain the focus of ongoing interference proceedings. Per the agreement, Illumina will have exclusive worldwide rights to use the pooled IP to develop and sell in-vitro diagnostic kits for NIPT and license third-party labs that want to develop and market their own NIPT tests under the pooled patents. Sequenom and Illumina both have rights to use all pooled patents to develop and sell their own NIPT and will share revenue from the patent pool, with Illumina paying Sequenom a royalty on sales of in-vitro diagnostic kits for NIPT. Illumina will pay Sequenom $50 million up front, as well as ongoing commitments for payments to Sequenom from the patent pool structure through 2020.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.